BCG未使用の高リスク非筋層浸潤性膀胱癌の参加者におけるTAR-200とセトレリマブまたはTAR-200単独と膀胱内カルメット・ゲラン菌(BCG)の併用の研究 (SunRISe-3)
第3相、非盲検、多施設、無作為化試験で、BCG未経験の高リスクの参加者を対象に、セトレリマブまたはTAR-200単独と膀胱内カルメット・ゲラン菌(BCG)との併用によるTAR-200の有効性と安全性を評価非筋層浸潤性膀胱がん
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).
調査の概要
詳細な説明
Bladder cancer is the tenth most common malignancy worldwide. About 75 percent (%) of bladder cancers are non-muscle invasive at diagnosis with approximately 25% of NMIBC patients have HR, NMIBC. The TAR-200/gemcitabine (JNJ-17000139) product is an intravesical drug delivery system regulated as an investigational drug. The drug constituent consists of gemcitabine and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The mainstay of treatment for HR-NMIBC is transurethral resection of bladder tumor, followed by intravesical treatment with BCG. In this study metronomic dosing of intravesical gemcitabine, delivered via TAR-200, alone or in combination with cetrelimab will be evaluated and compared against intravesical BCG. The study consists of a Screening phase, Treatment phase, and Follow-up phase. The total duration of the study will be up to 5 years and 2 months. Efficacy, Safety, pharmacokinetics (PK), and biomarkers will be assessed at specific time points during the study.
研究の種類
入学 (実際)
段階
- フェーズ 3
アクセスの拡大
連絡先と場所
研究場所
-
-
Arizona
-
Scottsdale、Arizona、アメリカ、85259
- Mayo Clinic
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72211
- Arkansas Urology
-
-
California
-
Long Beach、California、アメリカ、90822
- VA Long Beach Health Care System
-
Los Alamitos、California、アメリカ、90720
- Genesis Research, LLC - West Coast Urology
-
Los Angeles、California、アメリカ、90048
- Cedars Sinai Medical Center
-
Sacramento、California、アメリカ、95630
- UC Davis Comprehensive Cancer Center
-
San Diego、California、アメリカ、92123
- Genesis Research
-
Santa Monica、California、アメリカ、90404
- Providence Saint Johns Cancer Institute
-
Santa Rosa、California、アメリカ、95403
- Providence Medical Foundation
-
-
Colorado
-
Lakewood、Colorado、アメリカ、80228
- Colorado Clinical Research
-
-
Florida
-
Hialeah、Florida、アメリカ、33016
- Urological Research Network
-
Orlando、Florida、アメリカ、32806
- Orlando Health Cancer Institute
-
Sarasota、Florida、アメリカ、34239
- Sarasota Memorial Hospital
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30303
- Grady Memorial Hospital
-
Atlanta、Georgia、アメリカ、30322
- The Emory Clinic Department of Urology
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
Lisle、Illinois、アメリカ、60532
- Duly Health and Care
-
Quincy、Illinois、アメリカ、62301
- Blessing Hospital
-
-
Indiana
-
Carmel、Indiana、アメリカ、46032
- Urology of Indiana
-
Jeffersonville、Indiana、アメリカ、47130
- First Urology
-
-
Kansas
-
Merriam、Kansas、アメリカ、66204
- AMR Kansas City Oncology
-
Wichita、Kansas、アメリカ、67226
- Wichita Urology Group
-
-
Maryland
-
Hanover、Maryland、アメリカ、21076
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Burlington、Massachusetts、アメリカ、01805
- Lahey Hospital & Medical Center
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- University Of Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68114
- The Urology Center, PC
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- Cooper Health System MD Anderson Cancer Center at Cooper
-
-
New York
-
New York、New York、アメリカ、10029
- Icahn School of Medicine at Mt. Sinai
-
New York、New York、アメリカ、10010
- VA NY Harbor Healthcare System
-
Syracuse、New York、アメリカ、13210
- SUNY Upstate Med Univ
-
Syracuse、New York、アメリカ、13210
- Associated Medical Professionals of Ny
-
-
North Carolina
-
Greenville、North Carolina、アメリカ、27834
- Vidant Urology - Greenville
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic
-
Gahanna、Ohio、アメリカ、43230
- Central Ohio Urology Group
-
-
Pennsylvania
-
Bala-Cynwyd、Pennsylvania、アメリカ、19004
- Centers for Advanced Urology LLC d b a MidLantic Urology
-
Philadelphia、Pennsylvania、アメリカ、19107
- Thomas Jefferson University Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15232
- UPMC Shadyside Hospital
-
-
South Carolina
-
Myrtle Beach、South Carolina、アメリカ、29572
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University Medical Center
-
Nashville、Tennessee、アメリカ、37209
- Urology Associates
-
-
Texas
-
Austin、Texas、アメリカ、78745
- Urology Austin
-
Dallas、Texas、アメリカ、75231
- Urology Clinics of North Texas
-
Houston、Texas、アメリカ、77030
- Houston Methodist Hospital
-
Houston、Texas、アメリカ、77027
- Houston Metro Urology
-
San Antonio、Texas、アメリカ、78229
- Urology San Antonio Research
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute
-
Salt Lake City、Utah、アメリカ、84148
- George E. Wahlen VAMC
-
-
Virginia
-
Virginia Beach、Virginia、アメリカ、23462
- Urology Of Virginia, Pllc
-
-
Washington
-
Spokane、Washington、アメリカ、99202
- Spokane Urology
-
-
-
-
-
Buenos Aires、アルゼンチン、C1199
- Hospital Italiano de Buenos Aires
-
Buenos Aires、アルゼンチン、C1417
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
Córdoba、アルゼンチン、X5016KEH
- Hospital Privado Centro Medico de Cordoba
-
Córdoba、アルゼンチン、5000
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Córdoba、アルゼンチン、X5000KPH
- Centro Urologico Profesor Bengio
-
Mar del Plata、アルゼンチン、B7602CBM
- Hospital Privado de la Comunidad
-
Río Cuarto、アルゼンチン、5800
- Instituto Medico Rio Cuarto
-
-
-
-
-
Edinburgh、イギリス、EH4 2XU
- Western General Hospital
-
London、イギリス、W6 8RF
- Charing Cross Hospital
-
London、イギリス、SW3 6JJ
- The Royal Marsden NHS Trust
-
London、イギリス、EC1A 7BE
- St Bartholomews Hospital
-
Plymouth、イギリス、PL6 8DH
- Derriford Hospital
-
Scunthorpe、イギリス、DN15 7BH
- Scunthorpe General Hospital
-
Sheffield、イギリス、S10 2JF
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Stevenage、イギリス、SG1 4AB
- Lister Hospital
-
Truro、イギリス、TR1 3LJ
- Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
-
-
-
-
-
Acquaviva delle Fonti、イタリア、70021
- Generale Regionale F. Miulli
-
Asti、イタリア、14100
- Ospedale Cardinal Massaia
-
Avellino、イタリア、83100
- Ospedale San Giuseppe Moscati di Avellino
-
Castelfranco Veneto、イタリア、31033
- Ospedale San Giacomo Apostolo, Guardia pediatrica territoriale
-
Milan、イタリア、20141
- Istituto Europeo di Oncologia
-
Milan、イタリア、20132
- Ospedale San Raffaele di Milano
-
Naples、イタリア、80138
- Fondazione G Pascale Istituto Nazionale Tumori IRCCS
-
Ravenna、イタリア、48121
- Ospedale S. Maria Delle Croci
-
Rome、イタリア、00128
- Istituto Nazionale Tumori Regina Elena
-
-
-
-
-
Bangalore、インド、560027
- Health Care Global Enterprises pvt Ltd
-
Chandigarh、インド、160012
- Post Graduate Institute of Medical Education And Research PGIMER
-
Gurugram、インド、122001
- Artemis Hospital
-
Kolkata、インド、700094
- Netaji Subhas chandra Bose Cancer Research Institute
-
Mumbai、インド、400012
- Tata Memorial Hospital
-
Pune、インド、411040
- CIMET s Inamdar Multispeciality Hospital
-
-
-
-
-
Hoofddorp、オランダ、2134 TM
- Spaarne Gasthuis
-
Nijmegen、オランダ、6524 KD
- Canisius-Wilhelmina Ziekenhuis
-
Nijmegen、オランダ、6525 GA
- Radboud Umcn
-
-
-
-
-
Heidelberg、オーストラリア、3084
- Austin Health
-
Macquarie University、オーストラリア、2109
- Macquarie University Hospital
-
Nedlands、オーストラリア、6009
- Hollywood Private Hospital
-
South Brisbane、オーストラリア、4101
- Mater Hospital Brisbane
-
-
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3H 2Y9
- Nova Scotia Health Authority
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8N 4A6
- St Josephs Healthcare Hamilton
-
Toronto、Ontario、カナダ、M5G 1Z5
- Princess Margaret Cancer Centre University Health Network
-
-
Quebec
-
Montreal、Quebec、カナダ、H2X 3E4
- CHUM - Centre hospitalier universitaire de Montreal
-
Québec、Quebec、カナダ、G1J1Z4
- CHU de Quebec Universite Laval Hopital de l Enfant Jesus
-
Saint Jerome Quebec、Quebec、カナダ、J7Z 2V4
- Unite de Recherche Clinique du CISSS des Laurentides
-
-
-
-
-
A Coruña、スペイン、15006
- Hosp Univ A Coruna
-
Algeciras、スペイン、11207
- Hosp. Punta de Europa
-
Barcelona、スペイン、08025
- Fund. Puigvert
-
Cadiz、スペイン、11009
- Hosp. Puerta Del Mar
-
Castellon、スペイン、12004
- Hosp. Gral. Univ. de Castellon
-
L'Hospitalet de Llobregat、スペイン、08907
- Hosp. Univ. de Bellvitge
-
Lugo、スペイン、27003
- Hosp. Univ. Lucus Augusti
-
Madrid、スペイン、28041
- Hosp. Univ. 12 de Octubre
-
Madrid、スペイン、28046
- Hosp. Univ. La Paz
-
Madrid、スペイン、28027
- Clinica Univ. de Navarra
-
Málaga、スペイン、29010
- Hosp Virgen de La Victoria
-
Santander、スペイン、39008
- Hosp. Univ. Marques de Valdecilla
-
Valencia、スペイン、46010
- Hosp. Clinico Univ. de Valencia
-
-
-
-
-
Brno、チェコ、65691
- Fakultni nemocnice u sv. Anny v Brne
-
Hradec Králové、チェコ、500 05
- Fakultni nemocnice Hradec Kralove
-
Liberec、チェコ、460 01
- Krajská nemocnice Liberec a.s.
-
Olomouc、チェコ、779 00
- Fakultni nemocnice Olomouc
-
Prague、チェコ、100 34
- Fakultni nemocnice Kralovske Vinohrady
-
Prague、チェコ、15006
- Fakultni nemocnice v Motole
-
Prague、チェコ、140 59
- Thomayerova nemocnice, Onkologicka klinika
-
-
-
-
-
Cologne、ドイツ、50968
- Urologische Partnerschaft Koln UPK
-
Duisburg、ドイツ、47169
- Urologicum Duisburg
-
Erlangen、ドイツ、91054
- Universitatsklinikum Erlangen
-
Essen、ドイツ、45147
- Universitatsklinikum Essen
-
Frankfurt am Main、ドイツ、60590
- Universitaetsklinikum Frankfurt
-
Freiburg im Breisgau、ドイツ、79106
- Universitaetsklinikum Freiburg
-
Markkleeberg、ドイツ、04416
- Matthias Schulze - Germany
-
Mettmann、ドイツ、40822
- Urologie Neandertal Praxis Mettmann
-
München、ドイツ、81675
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Münster、ドイツ、48149
- Universitatsklinikum Munster
-
Nuremberg、ドイツ、90491
- Medizinisches Versorgungszentrum - Urologie
-
Nuremberg、ドイツ、90419
- Klinikum Nurnberg Nord
-
Nürtingen、ドイツ、72622
- Studienpraxis Urologie Nurtingen
-
Regensburg、ドイツ、93053
- Caritas-Krankenhaus St. Josef
-
Tübingen、ドイツ、72076
- Universitat Tubingen
-
-
-
-
-
Bordeaux、フランス、33000
- Polyclinique Bordeaux Nord Acquitaine
-
Clermont-Ferrand、フランス、63003
- CHU Gabriel-Montpied
-
Grenoble、フランス、38043
- CHU Grenoble
-
Limoges、フランス、87000
- Polyclinique de Limoges - Francois Chenieux
-
Lyon、フランス、69437
- Hôpital Edouard Herriot
-
Nantes、フランス、44093
- CHU de Nantes hotel Dieu
-
Nîmes、フランス、30029
- CHU Nimes
-
Orléans、フランス、45067
- Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source
-
Paris、フランス、75013
- Hôpital Universitaire Pitié-Salpêtrière
-
Paris、フランス、75018
- APHP - Hopital Bichat - Claude Bernard
-
Paris、フランス、75960
- Groupe Hospitalier Diaconesses Croix Saint Simon
-
Paris、フランス、75015
- Hopital Europeen Georges-Pompidou
-
Quint-Fonsegrives、フランス、31130
- Clinical La Croix Du Sud - Ramsay Santé
-
Rennes、フランス、35000
- Chu Rennes Hopital Pontchaillou
-
Strasbourg、フランス、67200
- Institut de Cancerologie Strasbourg Europe ICANS
-
Toulouse、フランス、31059
- CHU Rangueil
-
-
-
-
-
Barretos、ブラジル、14784-400
- Fundacao Pio XII
-
Bauru、ブラジル、17033-495
- NAIC Nair Antunes Instituto do Cancer
-
Campinas、ブラジル、13083-888
- Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP
-
Curitiba、ブラジル、81520-060
- Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
-
Natal、ブラジル、59075-740
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre、ブラジル、90050-170
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Presidente Prudente、ブラジル、19013-050
- Hospital Regional do Cancer Hospital de Esperanca
-
Salvador、ブラジル、41253-190
- IDOR - Regional Bahia
-
Santa Cruz do Sul、ブラジル、96835-090
- Hospital Ana Nery Santa Cruz do Sul
-
Santo André、ブラジル、09060-870
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo、ブラジル、01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo、ブラジル、01246 000
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
São Paulo、ブラジル、05652 900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo、ブラジル、1321 001
- Real e Benemerita Associacao Portuguesa de Beneficencia
-
-
-
-
-
Antwerp、ベルギー、2020
- ZNA Middelheim
-
Bruges、ベルギー、8000
- AZ Sint-Jan
-
Bruges、ベルギー、8310
- AZ Sint-Lucas
-
Ghent、ベルギー、9000
- AZ Maria Middelares
-
Ghent、ベルギー、9000
- UZ Gent
-
Libramont-Chevigny、ベルギー、6800
- Centre Hospitalier de l'Ardenne
-
Roeselare、ベルギー、8800
- AZ Delta
-
Sint-Niklaas、ベルギー、9100
- Vitaz
-
Wilrijk、ベルギー、2610
- GZA Ziekenhuizen- Campus St Augustinus
-
-
-
-
-
Coimbra、ポルトガル、3000-075
- Ipo Coimbra
-
Lisbon、ポルトガル、1769 001
- Uls Santa Maria - Hosp. Santa Maria
-
Vila Nova de Gaia、ポルトガル、4434 502
- Uls Gaia Espinho
-
-
-
-
-
Bialystok、ポーランド、15 276
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz、ポーランド、85 048
- IN VIVO Sp. z o.o
-
Lublin、ポーランド、20 708
- Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ
-
Piotrkow Trybunalski、ポーランド、97 300
- Centrum Medyczne
-
Poznan、ポーランド、61 731
- Clinical Research Center sp z o o MEDIC R s k
-
Słupsk、ポーランド、76-200
- Wojewodzki Szpital Specjalistyczny im Janusza Korczaka
-
Warsaw、ポーランド、02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Warsaw、ポーランド、02-647
- Provita Poliklinika
-
Wroclaw、ポーランド、50 556
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
-
-
-
-
-
Mexico City、メキシコ、14308
- Consultorio Medico dentro del Hospital Angeles Acoxpa
-
Monterrey、メキシコ、64460
- Hospital Universitario Dr Jose Eleuterio Gonzalez
-
Monterrey、メキシコ、64710
- Avix Investigacion Clinica S C
-
Mérida、メキシコ、97000
- Eme Red Hospitalaria
-
San Luis Potosí City、メキシコ、78260
- Oncologico Potosino
-
-
-
-
-
Beijing、中国、100730
- Beijing Hospital
-
Beijing、中国、100034
- Peking University First Hospital
-
Beijing、中国、101100
- Beijing Luhe Hospital, Capital Medical University
-
Changchun、中国、130499
- The First Bethune Hospital of Jilin University
-
Changsha、中国、410013
- Hunan Province Cancer Hospital
-
Chengdu、中国、610044
- West China Hospital Sichuan University
-
Chongqing、中国、400000
- Chongqing University Cancer Hospital
-
Deyang、中国、618000
- People's Hospital of Deyang City
-
Guangzhou、中国、430030
- Sun Yat Sen University Cancer Center
-
Hangzhou、中国、310000
- Zhejiang Provincial People's Hospital
-
Hangzhou、中国、310016
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Nanjing、中国、210008
- Nanjing Drum Tower Hospital
-
Ningbo、中国、315010
- The First Affiliated Hospital of Ningbo University
-
Shanghai、中国、200025
- Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
-
Shanghai、中国、200400
- Huadong Hospital Affiliated to Fudan University
-
Shenyang、中国、110004
- Shengjing Hospital Of China Medical University
-
Tianjin、中国、300211
- The Second Hospital Of Tianjin Medical University
-
Wenzhou、中国、325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan、中国、430030
- TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
-
Xi'an、中国、710061
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University
-
Yantai、中国、264000
- Yantai Yuhuangding Hospital
-
Zhengzhou、中国、450008
- Henan Cancer Hospital
-
-
-
-
-
Kaohsiung City、台湾、833
- Chang Kung Memorial Hospital
-
Kaohsiung City、台湾、807
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Taichung、台湾、404
- China Medical University Hospital
-
Taichung、台湾、40705
- Taichung Veterans General Hospital
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
Taoyuan、台湾、33382
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Fuji-shi、日本、417-8567
- Fuji City General Hospital
-
Kanazawa、日本、920 8641
- Kanazawa University Hospital
-
Kashihara-shi、日本、634-8522
- Nara Medical University Hospital
-
Kisarazu-shi、日本、292-8535
- Kimitsu Chuo Hospital
-
Kobe、日本、650 0047
- Kobe City Medical Center General Hospital
-
Kumamoto、日本、860-0008
- National Hospital Organization Kumamoto Medical Center
-
Nagano、日本、381-8551
- Nagano Municipal Hospital
-
Nagasaki、日本、852-8501
- Nagasaki University Hospital
-
Nagasaki、日本、852-8511
- JRC Nagasaki Genbaku Hospital
-
Narashino-shi、日本、275-8580
- Saiseikai Narashino Hospital
-
Toon-shi、日本、791-0295
- Ehime University Hospital
-
Toyama、日本、930 0194
- Toyama University Hospital
-
Ube、日本、755-8505
- Yamaguchi University Hospital
-
Yokohama、日本、232 0024
- Yokohama City University Medical Center
-
-
-
-
-
Busan、韓国、49241
- Pusan National University Hospital
-
Cheongju-si、韓国、28644
- Chungbuk National University Hospital
-
Daegu、韓国、41404
- Kyungpook National University Chilgok Hospital
-
Daegu、韓国、42601
- Keimyung University Dongsan Hospital
-
Gyeonggi-do、韓国、10408
- National Cancer Center
-
Jeollanam-do、韓国、58128
- Chonnam National University Hwasun Hospital
-
Seoul、韓国、03080
- Seoul National University Hospital
-
Seoul、韓国、03722
- Severance Hospital Yonsei University Health System
-
Seoul、韓国、06351
- Samsung Medical Center
-
Seoul、韓国、03181
- Kangbuk Samsung Hospital
-
Seoul、韓国、06591
- The Catholic University of Korea Seoul St Marys Hospital
-
Seoul、韓国、02841
- Korea University Anam Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically confirmed initial diagnosis by local pathology (within 90 days of the most recent signed informed consent) of high grade non-muscle invasive bladder cancer (HR-NMIBC) (high-grade Ta, any T1 or carcinoma in-situ [CIS]), in participants who are Bacillus Calmette Guérin (BCG)-naïve
- BCG-naïve (participants who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before date of randomization are eligible)
- All visible papillary disease must be fully resected (absent) prior to date of randomization and documented at baseline cystoscopy. Local urine cytology at screening must be negative or atypical (for high-grade urothelial carcinoma [HGUC]) for patients with papillary only disease (without CIS)
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
- All adverse events associated with any prior surgery and/or intravesical therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (<) 2 prior to date of randomization
- Participants must be willing to undergo all study procedures
Exclusion Criteria:
- Presence or history of histologically confirmed, muscle invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, greater than and equal to [>=] T2)
- Must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder (that is, urethra, ureter, or renal pelvis). Ta/any T1/CIS of the upper urinary tract (including renal pelvis and ureter) is allowable if treated with complete nephroureterectomy more than 24 months prior to randomization
- Presence of any bladder or urethral anatomic feature (example, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-200 or administration of intravesical BCG. Participants with tumors involving the prostatic urethra in men will be excluded
- A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (mL)
- Indwelling catheters are not permitted; however, intermittent catheterization is acceptable
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment Group A: TAR-200 + Cetrelimab
Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab. |
Cetrelimab will be administered.
他の名前:
TAR-200 will be administered intravesically.
他の名前:
|
|
アクティブコンパレータ:Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture
Participants will receive intravesical BCG once every week for 6 weeks (induction) and then followed by once every week for 3 weeks starting at Weeks 12, 24, 48, 72, and 96 (maintenance). |
BCG will be administered intravesically. |
|
実験的:Treatment Group C: TAR-200 Alone
Participants will receive intravesical TAR-200 alone once Q3W. |
TAR-200 will be administered intravesically.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Event-free Survival (EFS)
時間枠:Up to 5 years 2 months
|
EFS is defined as the time from randomization to either the time of the first recurrence of high-risk disease, progression, or death due to any cause, whichever occurs first. For participants with carcinoma In-situ (CIS), persistent disease at 6 months (Week 24) is also considered an EFS event. Progression is defined as: an increase of stage from Ta to T1 or from CIS to T1 or progression to muscle invasive bladder cancer (MIBC) (T greater than or equal to [>=] 2) or to lymph node (N+) or to distant disease (M+), whichever occurs first. |
Up to 5 years 2 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Complete Response (CR) Rate
時間枠:Up to 5 years 2 months
|
Overall CR will be measured by determining the percentage of participants with CIS who have no presence of high-risk disease at 6 months. |
Up to 5 years 2 months
|
|
Duration of CR
時間枠:Up to 5 years 2 months
|
Duration of CR is defined from the time of first CR achieved to first evidence of recurrence, progression or death due to any cause (whichever occurs first) for participants who achieve a CR. |
Up to 5 years 2 months
|
|
Recurrence-Free Survival (RFS)
時間枠:Up to 5 years 2 months
|
RFS is defined as the time from randomization to the time of the first recurrence of high-risk disease, or death due to any cause, whichever occurs first. |
Up to 5 years 2 months
|
|
Time to Progression (TTP)
時間枠:Up to 5 years 2 months
|
TTP is defined as the time from randomization to the date of first documented evidence of disease progression or death due to disease progression, whichever occurs first. |
Up to 5 years 2 months
|
|
Overall Survival (OS)
時間枠:Up to 5 years 2 months
|
OS is defined as the time from randomization to death, due to any cause. |
Up to 5 years 2 months
|
|
Cancer Specific Survival (CSS)
時間枠:Up to 5 years 2 months
|
CSS is defined as the time from randomization to the date of death due to bladder cancer. |
Up to 5 years 2 months
|
|
Number of Participants with Adverse Events (AEs) by Grades According to Common Terminology Criteria for Adverse Events (CTCAE)
時間枠:Up to 5 years 2 months
|
Number of participants with AEs by severity grade as assessed by CTCAE version 5 will be reported. Grade refers to the severity of AE as follows: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5- Death related to adverse event. |
Up to 5 years 2 months
|
|
Number of Participants with Adverse Events (AEs)
時間枠:Up to 5 years 2 months
|
Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. |
Up to 5 years 2 months
|
|
Number of Participants with Change from Baseline in Laboratory Abnormalities
時間枠:Up to 5 years 2 months
|
Number of participants with change from baseline in laboratory abnormalities will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe, Grade 4- Life-threatening, and Grade 5- Death related to adverse event. |
Up to 5 years 2 months
|
|
Number of Participants with Change from Baseline in Vital Signs Abnormalities
時間枠:Up to 5 years 2 months
|
Number of participants with change from baseline in vital signs (blood pressure [systolic and diastolic], heart rate, temperature, and weight) abnormalities will be reported. |
Up to 5 years 2 months
|
|
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of life Questionnaire - Non-muscle Invasive Bladder Cancer EORTC QLQ- NMIBC 24
時間枠:Up to 5 years 2 months
|
EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the Health-related quality of life (HRQoL) of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the quality of life questionnaire (QLQ-C30) and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). |
Up to 5 years 2 months
|
|
Time to Symptom Deterioration as Assessed by EORTC-QLQ-NMIBC 24 Scores
時間枠:Up to 5 years 2 months
|
EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the HRQoL of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the QLQ-C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). |
Up to 5 years 2 months
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CR109223
- 2020-004506-64 (EudraCT番号)
- 17000139BLC3002 (その他の識別子:Janssen Research & Development, LLC)
- 2023-507187-39-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。